


Product Details

Product name:	Anti-human VEGF (bevacizumab Biosimilar)	SKU:	BIO0079SM
Target Name:	VEGF	Size:	1 mg/5 mg/20 mg
Target Uniprot:	P15692	Concentration:	Lyophilized
Clone#:	bevacizumab	Isotype:	Human IgG1
Reactivity:	Human	Calculated M.W.:	146.5 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	0.1M Pro, 20mM Arg, pH5.0	Conjugation:	None
Storage:	For long term storage, the produce should be stored at -20° C or lower.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH2O	Purification:	Protein A


Data

Purity:SDS-PAGE




Anti-VEGF (BioMab patent anti-VEGF) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC




The purity of Anti-VEGF (BioMab patent anti-VEGF) is 97.8%, determined by SEC-HPLC.

Bioactivity:ELISA



Immobilized human VEGF165 His at 2 µg/mL can bind Anti-VEGF (BioMab patent anti-VEGF), EC₅₀=0.003018 µg/mL.

Research in vivo



Bevacizumab inhibited the tumor growth of COLO205 on balb/c nude mice. The result showed significant anti-tumor effects, with a tumor inhibition rate (TGI) of 42.0% at 0.95 mpk at D31.